Spotlight on global cancer control at ASCO 2022

UICC announces global coalition to increase access to essential cancer medicines in low and lower middle-income countries

Comment: LUMINA results show that women with low levels of the Ki67 biomarker can avoid outcomes related to radiotherapy

Momelotinib superior to danazol in symptomatic and anaemic myelofibrosis patients previously treated with a JAK inhibitor

Biomarker analysis of the NeoALTTO trial provides oncofertility insight for younger breast cancer patients

Elacestrant significantly prolongs PFS for ER+/HER2- metastatic breast cancer without prior chemotherapy patients

ASCO 2022: Breast cancer highlights

Neoadjuvant ipilimumab and nivolumab immunotherapy could become new standard of care for resectable stage III melanoma

CheckMate 9ER: aRCC patients on nivolumab plus cabozantinib achieved deeper responses vs sunitinib

Pancreatic neuroendocrine tumours: Capecitabine plus temozolomide gives longer PFS than temozolomide alone

ctDNA sequencing detects outcomes for pretreated advanced gastrointestinal stromal tumour

Adjuvant endocrine therapy used to treat ER+ HER2- breast cancer